Pictet Asset Management Ltd. boosted its stake in shares of Boston Scientific Corporation (NYSE:BSX) by 4.6% during the second quarter, Holdings Channel reports. The institutional investor owned 1,275,775 shares of the medical equipment provider’s stock after buying an additional 56,098 shares during the period. Pictet Asset Management Ltd.’s holdings in Boston Scientific Corporation were worth $34,484,000 at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of BSX. Goelzer Investment Management Inc. purchased a new stake in Boston Scientific Corporation during the second quarter valued at about $2,117,000. Retirement Systems of Alabama increased its stake in shares of Boston Scientific Corporation by 0.3% in the second quarter. Retirement Systems of Alabama now owns 1,404,418 shares of the medical equipment provider’s stock valued at $38,930,000 after buying an additional 4,875 shares during the period. IFP Advisors Inc increased its stake in shares of Boston Scientific Corporation by 30.4% in the second quarter. IFP Advisors Inc now owns 9,077 shares of the medical equipment provider’s stock valued at $252,000 after buying an additional 2,114 shares during the period. Korea Investment CORP increased its stake in shares of Boston Scientific Corporation by 8.1% in the second quarter. Korea Investment CORP now owns 2,491,462 shares of the medical equipment provider’s stock valued at $69,063,000 after buying an additional 185,877 shares during the period. Finally, Sei Investments Co. increased its stake in shares of Boston Scientific Corporation by 6.6% in the second quarter. Sei Investments Co. now owns 5,432,365 shares of the medical equipment provider’s stock valued at $150,586,000 after buying an additional 334,459 shares during the period. Hedge funds and other institutional investors own 92.08% of the company’s stock.

Shares of Boston Scientific Corporation (BSX) opened at 26.57 on Thursday. The firm’s 50-day moving average price is $27.43 and its 200 day moving average price is $26.02. Boston Scientific Corporation has a 1-year low of $19.67 and a 1-year high of $28.51. The stock has a market capitalization of $36.41 billion, a P/E ratio of 47.53 and a beta of 1.09.

Boston Scientific Corporation (NYSE:BSX) last posted its quarterly earnings results on Thursday, July 27th. The medical equipment provider reported $0.32 EPS for the quarter, topping the Zacks’ consensus estimate of $0.31 by $0.01. The business had revenue of $2.26 billion during the quarter, compared to the consensus estimate of $2.21 billion. Boston Scientific Corporation had a return on equity of 23.62% and a net margin of 9.04%. The company’s revenue for the quarter was up 6.2% compared to the same quarter last year. During the same period last year, the firm earned $0.27 earnings per share. Analysts expect that Boston Scientific Corporation will post $1.26 EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “Boston Scientific Corporation (NYSE:BSX) Shares Bought by Pictet Asset Management Ltd.” was originally reported by Daily Political and is owned by of Daily Political. If you are accessing this article on another website, it was illegally stolen and republished in violation of U.S. and international copyright law. The legal version of this article can be viewed at https://www.dailypolitical.com/2017/08/10/boston-scientific-corporation-nysebsx-shares-bought-by-pictet-asset-management-ltd.html.

Several equities research analysts have weighed in on BSX shares. Guggenheim restated a “buy” rating on shares of Boston Scientific Corporation in a report on Wednesday, April 12th. Zacks Investment Research raised Boston Scientific Corporation from a “sell” rating to a “hold” rating in a research report on Monday, April 24th. TheStreet raised Boston Scientific Corporation from a “c+” rating to a “b” rating in a research report on Tuesday, April 25th. Needham & Company LLC reaffirmed a “buy” rating and set a $30.00 price objective (up from $29.00) on shares of Boston Scientific Corporation in a research report on Thursday, April 27th. Finally, Oppenheimer Holdings, Inc. set a $27.00 price objective on Boston Scientific Corporation and gave the stock a “hold” rating in a research report on Friday, April 28th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating, fourteen have issued a buy rating and one has given a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average target price of $30.06.

In other Boston Scientific Corporation news, EVP Michael P. Phalen sold 15,500 shares of Boston Scientific Corporation stock in a transaction that occurred on Thursday, June 29th. The stock was sold at an average price of $28.02, for a total value of $434,310.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Kevin J. Ballinger sold 28,864 shares of Boston Scientific Corporation stock in a transaction that occurred on Wednesday, May 17th. The shares were sold at an average price of $26.14, for a total value of $754,504.96. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 236,489 shares of company stock valued at $6,440,888. 0.74% of the stock is currently owned by insiders.

Boston Scientific Corporation Company Profile

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology.

Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Corporation (NYSE:BSX).

Institutional Ownership by Quarter for Boston Scientific Corporation (NYSE:BSX)

Receive News & Ratings for Boston Scientific Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific Corporation and related companies with MarketBeat.com's FREE daily email newsletter.